Trending:Satya Nadella sells half his Microsoft stock, weeks before state implements capital gains tax
Alexandria Executive Chairman Joel Marcus. (Alexandria Real Estate Equities Photo)

乔尔·马库斯(Joel Marcus)’ fortunes have risen with those of the life sciences industry. The executive chairman of life sciences builderAlexandria Real Estate Equities首先在西雅图购买了实验室空间in 1996, two years after founding the company when biotech was still emerging as an industry.

Alexandria is now a publicly traded giant with a market cap of more than $30 billion, millions of square feet of lab space throughout the U.S. and a venture capital arm,亚历山大风险投资。他的加利福尼亚州帕萨迪纳(Pasadena)的公司帮助使西雅图地区成为该国的一员top ten biotech clusters

Just as Marcus saw the rise of biotech and capitalized on it, he is reading the tea leaves as the pandemicfuels investor interestin biotech and upends business models. He talked about the future of the industry in Seattle and beyond in an interview with Life Science Washington CEO Leslie Alexandre, at the trade group’s年度峰会上周。

仅在西雅图,该公司的建筑物Sana Biotechnology,new headquarters自适应生物技术,实验室对弗雷德小屋chinson Cancer Research Center, to name a few. It built the headquarters for Juno Therapeutics, the cell therapy biotech acquired by Celgene for$9 billion in 2018, and is developing a life sciences hub at Seattle’salmost three-acre Mercer Mega Block.它的风险投资支持西雅图公司Silverback Therapeuticsand cell therapy startupUmoja Biopharma

Alexandria is alsosnapping up real estatein nearby Bothell, Wash., where it houses the headquarters of global biotech Seagen.

Marcus spoke with Alexandre about the rise of a “spoke and hub” model of business, the growth of biotech clusters, and the need to shore up supply chains. The pandemic also revealed the need for complex therapeutics, making the Seattle area well positioned to forge the next generation of medicines.

Read one for highlights from the interview below, edited for clarity and brevity.

生物技术clusters will strengthen

乔尔·马库斯(Joel Marcus):“人才的战争就是一切。如果您是一家公司,那么您将不会在没有人才库的地方开始。您无法在新城市建立公司。您可以将一家小型公司放在一起,并且可以在一定程度上种植它,但是您不能以任何有意义的方式扩展它。我认为现有的集群将变得更加占主导地位。”

New company structures will rise


“Given that talent is moving around with COVID, I think there are going to be more spoke and hub situations with companies. So you could have a Seattle company that has a San Francisco presence, and maybe a Boston presence. We already see that with a number of companies, Sana is a great example.” (Sana is headquartered in Seattle but is hiring in the Boston and San Francisco biotech clusters, and is building amanufacturing facilityin the Bay Area.)

Seattle has brains and talent

“We’ve always felt Seattle was a truly remarkable place and I think today we see it as an amazing region. This intersection of technology and life science is pretty big. It’s a world class location with great science.

Risk capital, there’s a lot of it — but it’s probably not nearly as strong as some of the other regions, so that’s something that needs enhancement.

And then you’re seeing some great waves with management talent creating new companies. People who started and grew up at Juno and so many other companies have now helped seed and start other companies. And that’s a really good thing. But I think governance in Seattle today is a big question.”

Workers are looking beyond urban areas

Related:Are tech employees coming back to downtown Seattle? Here’s what companies are planning for.

“When you look at the greater Puget Sound area, I think you have to recognize that people are nervous about living in urban areas today that are not well governed. And there are some parts of Seattle, you go down to Pioneer Square and it’s a pretty rough area down there, and that’s true of a number of locations.”

Bothell, Wash. has room to grow

“Seagen has been an anchor up there for decades and has done a great job of growing this ecosystem. Bothell’s been an important place. I think today in the world of next-gen manufacturing for gene and cell therapy, Bothell represents a great place for these companies to expand and create these critical facilities that are really needed.”

Shoring up supply chains for the 21stcentury


Preparing for developing complex therapeutics

“The second part, in addition to what COVID exposed with supply chain issues, is that the future of medicine is complex medicines, next-gen medicines. And it’s in gene therapy, cell therapy and beyond. And we need to have that control [of the supply chain], and I think Washington, and particularly the Puget Sound region, has a great opportunity there.”

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Job Listings on GeekWork

Find more jobs onyabo10 。Employers,post a job here